上海蔼睦医疗科技有限公司 Mediaroom

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company d...

2024-02-19 09:00 3518

AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

SHANGHAI, Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology co...

2023-10-31 09:35 2090

AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL

Expands Portfolio of Cataract Surgery Solutions for Patients in Greater China to New Extended Monof...

2023-10-10 09:00 2565

AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD

SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology c...

2023-09-25 09:00 2458

AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology c...

2023-09-20 09:00 2413

AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over...

2023-08-10 15:49 4417

AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients

SHANGHAI, May 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology com...

2023-05-31 11:39 2202

AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema

* AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a singl...

2023-05-25 15:52 2688

AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, April 17, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology c...

2023-04-17 09:00 4493

AffaMed Technologies Announces TFDA Approval of MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready IOLs for Cataract Treatment in Taiwan

SHANGHAI, March 20, 2023 /PRNewswire/ -- AffaMed Technologies, a joint venture established between ...

2023-03-20 09:00 3035

AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL

SHANGHAI, March 3, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a joint venture establish...

2023-03-03 09:00 3887

AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galca...

2023-01-17 08:00 4965

AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease

SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage bi...

2022-05-31 11:30 1484

AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau

SHANGHAI, May 9, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage bio...

2022-05-10 09:00 1673

AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage ...

2022-04-13 10:46 1882

AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 - a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases

SHANGHAI, Feb. 15, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage b...

2022-02-15 15:05 1352

AffaMed Therapeutics Announces the Establishment of AffaMed Digital to Advance Digital Medicines

SHANGHAI, Nov. 10, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage t...

2021-11-10 15:00 1822

AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases

BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage b...

2021-09-06 08:00 1288

AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease

SHANGHAI, May 27, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage bi...

2021-05-28 08:00 1545

AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer

SHANGHAI, May 17, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage bi...

2021-05-17 08:10 3304

Latest News